Research Tools Sample Clauses

Research Tools. (a) During each Research Term, each Party or its designee (the “Research Tool Disclosing Party”) may transfer to the other Party or its designee (the “Research Tool Receiving Party”) certain control molecules, recombinant proteins, cell lines, assays or other research related Materials (“Research Tools”) as necessary for the Research Tool Receiving Party to perform its assigned activities under each Research Program as expressly set forth in each Research Plan.
Sample 1Sample 2
AutoNDA by SimpleDocs
Research Tools. HFS may provide some general research tools and third party-provided information for your use. Although HFS attempts to identify the sources of all of the information and other material provided to you and HFS believes that those sources are reliable, we do not check for accuracy. NONE OF THESE TOOLS OR INFORMATION ARE CUSTOMIZED FOR YOU, and HFS is not making individualized recommendations about the suitability of purchases or sales of any of the securities or investment strategies that may be listed, analyzed, referenced or identified in the use of the tools or information. HFS investment representatives may be contacted directly to assist you in learning how to properly use the research tools available through HFS. However, those representatives will not advise you about the suitability of any particular security, transaction, investment or strategy in light of your particular financial circumstances and investment objectives even where the representative may know them.
Sample 1
Research Tools. The parties acknowledge that the SMA research and clinical communities will benefit from the availability of Research Tools. Company agrees to use commercially reasonable efforts to make Research Tools Controlled by it available to members of the spinal muscular atrophy research and clinical communities (excluding for-profit entities engaged in pharmaceutical research and development) for research or educational purposes on commercially reasonable terms as promptly as practicable following request by the Foundation or such person (it being understood that neither Company nor its corporate partners shall charge reach-through royalties with respect to drugs discovered by such persons using Research Tools, so long as such drugs themselves are not covered by Company Technology); provided, however, that Company shall not have any obligation to provide such access before the publication of patent applications containing claims (adequately supported by written description) that cover the relevant Research Tool. Notwithstanding the foregoing, if Company believes in good faith that [**], then Company shall so notify the Foundation in writing, and the parties shall discuss in good faith how to proceed. ​
Sample 1
Research Tools. In the event that Sponsor exercises its option to obtain a non-exclusive license to Research Tools under Section 3.1b herein above and elects not to pursue patent protection on such Research Tools, TSRI and Sponsor shall have sixty (60) days from the date of exercise of option by Sponsor in which to execute a license agreement to such Research Tools. This shall in no way restrict TSRI’s right to obtain patent protection on such Research Tools.
Sample 1
Research Tools. AFS may provide some general research tools and third party-provided information for your use. Although AFS attempts to identify the sources of all of the information and other material provided to you and AFS believes that those sources are reliable, we do not check for accuracy. NONE OF THESE TOOLS OR INFORMATION ARE CUSTOMIZED FOR YOU, and AFS is not making individualized recommendations about the suitability of purchases or sales of any of the securities or investment strategies that may be listed, analyzed, referenced or identified in the use of the tools or information. AFS investment representatives may be contacted directly to assist you in learning how to properly use the research tools available through AFS. However, those representatives will not advise you about the suitability of any particular security, transaction, investment or strategy in light of your particular financial circumstances and investment objectives even where the representative may know them. Idle Account Funds. Unless otherwise directed by you, all idle funds held within your account will automatically be invested (“swept”) into the Alight Money Market Fund. If you wish to invest the funds held in Alight Money Market Fund shares into other securities, it is your responsibility to monitor available balances in the shares and to direct AFS personnel to make the appropriate transactions, subject to the restrictions placed on the account by the fiduciaries. All pertinent information, including statements about investment policies, risks, considerations, charges, and expenses, pertaining to the Alight Money Market Fund can be found in the Alight Money Market Fund prospectus, as it may be amended from time to time. A free copy of this prospectus is available by contacting an AFS representative or by visiting xxx.xxxxxxxxxxxxxxxxxxxxxxxx.xxx. Please note that AFS and AFS’ parent company, Alight Solutions LLC (“Alight Solutions”), each receive compensation for the services that they provide, respectively, to the Alight Money Market Fund. These arrangements are described thoroughly in the prospectus. Neither AFS nor Alight Solutions are banks, and shares of the Alight Money Market Fund are not obligations of, or endorsed or guaranteed by, any bank or other depository institution, nor are they insured by the Federal Deposit Insurance Corporation (FDIC), the Federal Reserve Board, or any government agency. Although the Alight Money Market Fund seeks to preserve the value of your invest...
Sample 1
Research Tools. Guidance Note for section 5 of Schedule 3: This section is not intended to be exhaustive, but allows the parties to specify their Materials/ Research Tools for clarity. No rights are granted to the parties in relation to the Research Tools (as Research Tools are excluded from the definition of Pre-existing IPR). Contributing Party Description Use in the Project Guidance Note for section 5.2 of Schedule 3: Each party provides a licence to the other parties to Use its Pre-existing IPR (see clause 9.2). If a party wants to impose restrictions on the other parties' Use of its Pre-existing IPR, the restrictions should be set out in this section. If the Pre-existing IPR is likely to be incorporated into the Project IP or be used by a party as part of its role in the Project, any restrictions should be carefully considered to avoid restricting a party in using the Project IP or undertaking the Project.
Sample 1
Research Tools 
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs

Related to Research Tools

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Licensed Software Computer program(s) provided by Contractor in connection with the Deliverables, subject to Section 14 of this Contract.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Third Party Technology The Company makes use of third party technology to collect information required for traffic measurement, research, and analytics. Use of third party technology entails data collection. We therefore would like to inform clients the Company enables third parties to place or read cookies located on the browsers of users entering the Company’s domain. Said third parties may also use web beacons to collect information through advertising located on the Company’s web site. Please note that you may change your browser settings to refuse or disable Local Shared Objects and similar technologies; however, by doing so you may be disabling some of the functionality of Company’s services.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • New Technology When new or updated technology is introduced into a workplace, it will be the responsibility of the employer to provide appropriate and, if necessary, ongoing training to the employees directly affected. Such training will include any health and safety implications or information that will enable employees to operate the equipment without discomfort and will help maintain their general well-being.

Time is Money Join Law Insider Premium to draft better contracts faster.